DHA, Boehringer Ingelheim Set Guinness World Records Title for Largest Light Mosaic.

Dubai: Boehringer Ingelheim, a leading research-driven biopharmaceutical company, in collaboration with the Dubai Health Authority (DHA), has set a Guinness World Records title for creating the 'Largest light mosaic (image)'. The event took place at Dubai Festival City Mall on November 16th, featuring a mosaic that highlighted the connections between cardiovascular, renal, and metabolic (CRM) diseases. The initiative aimed to raise awareness about the importance of early diagnosis and holistic management of CRM diseases.According to Emirates News Agency, more than one billion people worldwide live with CRM diseases such as heart failure, chronic kidney disease, and type 2 diabetes. These diseases are interconnected, often co-existing and intensifying each other's effects, thus heavily impacting patients' lives. This interconnectivity was visually represented through a vibrant mosaic made entirely from energy-efficient LED light bulbs, showcasing the heart, kidneys, and pancreas linked together.The initiat ive focused on improving care for CRM diseases. DHA health educators were present to provide information on risk factors and emphasize the importance of early detection and comprehensive management. The public was encouraged to take proactive steps by staying informed and consulting healthcare professionals if any concerns arose.Participants who engaged with DHA health educators were invited to contribute to the record-breaking mosaic by adding a light bulb, symbolizing newfound hope and awareness. Celebrity Kris Fade participated in the activity to further spread these vital messages. Each bulb added represented hope and served as a reminder of the transformative power of scientific advancements.Derek O'Leary, Regional Managing Director at Boehringer Ingelheim for the India, Middle East, Turkiye, and Africa (IMETA) region, expressed the company's commitment to alleviating the burden of CRM diseases in the UAE and the broader region. He highlighted the importance of collaborative efforts in improving the lives of patients and expressed pride in partnering with the DHA to make a positive impact on communities.Dr. Mohamed Meshref, Medical Director at Boehringer Ingelheim for the IMETA region, emphasized the significance of raising awareness about the interconnected nature of CRM diseases and their risk factors. He noted that addressing these diseases early and holistically can help prevent severe complications and slow disease progression. He also encouraged patients to adopt healthy lifestyle choices to enhance their overall well-being.Boehringer Ingelheim continues to lead as a biopharmaceutical company committed to innovation and developing breakthrough therapies for patients living with CRM diseases. The company remains dedicated to transforming lives for future generations through scientific advancements.